Journal article
Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure
Clinical lymphoma, myeloma and leukemia, Vol.25(12), pp.e1007-e1013
12/2025
DOI: 10.1016/j.clml.2025.06.015
Abstract
While B cell maturation antigen (BCMA) directed therapies are increasingly utilized for multiple myeloma, outcomes with sequential therapies with BCMA directed treatments remains an area of active investigation. In this multicenter retrospective analysis, we evaluated the real-world outcomes of patients treated with BCMA directed therapies including CAR T and bispecific antibody (BsAb) following progression on an antibody drug conjugate belantamab mafodotin. A total of 23 patients (14 CAR T, 9 BsAb), were included in the analysis. The median patient age was 68 (range 37-82) years with 43% with high-risk cytogenetics, 87% had received at least ≥4 prior lines of treatment, and 35% had extra medullary disease at the time of treatment. The overall response rate (ORR) for the entire population was 65%, 44% in the BsAb and 79% in the CAR-T subgroup. With a median follow up of 24 months, median PFS and OS were 5 (2-10) months and 28 (16-NR) months, respectively. There was no difference in median PFS between patients who received a BsAb (5 mos, range 2-10) versus CAR T (7 mos range 2-9) (p= 0.8) or received BCMA directed therapy < 6 months (5 mos, range 3-9) versus ≥ 6 month post belantamab (7 mos, range 2-10) (p= 0.8). Treatment with BCMA directed BsAb or CAR T remains feasible for RRMM patients after progression on belantamab, However, outcomes in general remain inferior compared to those without prior BCMA exposure and were not affected by choice of therapy or time since last BCMA exposure.
Details
- Title: Subtitle
- Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure
- Creators
- Prerna Mewawalla - Allegheny Health NetworkRachel Dileo - Allegheny Health NetworkYue Yin - Allegheny-Singer Research InstituteChristopher Strouse - University of IowaHira Shaikh - University of IowaJames A Davis - Medical University of South CarolinaOmar Alkharabsheh - University of South AlabamaAliya Rashid - The University of Kansas Cancer CenterNausheen Ahmed - The University of Kansas Cancer CenterAl-Ola Abdallah - The University of Kansas Cancer CenterHamza Hashmi - Medical University of South Carolina
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.25(12), pp.e1007-e1013
- DOI
- 10.1016/j.clml.2025.06.015
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Electronic publication date
- 06/2025
- Date published
- 12/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984843595102771
Metrics
28 Record Views